Trial reportDrug design, development and therapy2025
Liposomal Bupivacaine in Ultrasound-Guided Paravertebral Block Reduces Opioid Consumption and Accelerates Recovery After Thoracic Surgery: A Randomized Controlled Trial.
Trial report in Drug design, development and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Intercostal nerve block with liposomal bupivacaine versus no regional analgesia after uniportal thoracoscopic surgery: A randomized controlled trial.JTCVS open · 2026Trial
- Anterior Quadratus Lumborum Block with Liposomal Bupivacaine versus Ropivacaine for Postoperative Recovery in Laparoscopic Colorectal Surgery: A Randomized Controlled Trial.Drug design, development and therapy · 2026Trial
- Efficacy of erector spinae plane block with liposomal bupivacaine for postoperative analgesia in patients undergoing open spinal surgery: a randomized controlled trial.Frontiers in pharmacology · 2026Trial
- Liposomal bupivacaine versus ropivacaine thoracic paravertebral block for thoracoscopic atrial septal defect repair: analgesic efficacy and cardiac biomarker outcomes in a single-center, assessor-blinded, randomized trial.Journal of thoracic disease · 2026Article
- Recent advances in thoracic anesthesia: lung protection, airway management, and enhanced recovery-a narrative review.Journal of thoracic disease · 2026Review
- Liposomal Bupivacaine in Perioperative Analgesia: A Comprehensive Review of Clinical Efficacy, Safety, and Economic Context.Current pain and headache reports · 2026Review
- Liposomal Bupivacaine Versus Ropivacaine in Combined Thoracic Paravertebral Block and Serratus Anterior Plane Block for Thoracoscopic Surgery: A Randomized Controlled Trial.The Kaohsiung journal of medical sciences · 2026Article
- Ultrasound-Guided Thoracic Paravertebral Block With Liposomal Versus Standard Bupivacaine for Older Patients After Thoracoscopic Surgery.The Kaohsiung journal of medical sciences · 2026Article
- Liposomal bupivacaine for postoperative analgesia after thoracoscopic surgery: a systematic review and meta-analysis.Journal of thoracic disease · 2026Article
- Liposomal Bupivacaine Combined with Bupivacaine vs Ropivacaine for Paravertebral Blockade in Single-Port Video-Assisted Thoracoscopic Surgery: A Propensity-Matched Comparison of Postoperative Opioid Use.Drug design, development and therapy · 2026Article
- Evolving Trends and Core Contributors: A Bibliometric Update on Liposomal Bupivacaine.Pain research & management · 2026Article
- Liposomal bupivacaine in thoracic surgery: a comprehensive review of current evidence and clinical implications.Frontiers in medicine · 2026Review
- Efficacy of repetitive transcranial magnetic stimulation on postoperative pain in patients undergoing video-assisted thoracoscopic surgery: study protocol for a prospective, single-center, randomized controlled trial.Frontiers in medicine · 2026Article
- Effect of Liposomal Bupivacaine in Peripheral Nerve Block Following Thoracoscopic Lung Surgery: A Systematic Review and Meta-Analysis.Journal of pain research · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Liposomal bupivacaine (LB) can provide prolonged analgesia, which may reduce patients' opioid consumption, improve comfort, and facilitate recovery. Looser tissue and lower vascularity in the paravertebral space may facilitate LB diffusion and duration, so we investigated the effects of LB in multimodal analgesia after thoracic surgery with paravertebral block. Methods: In this single-center, double-blind, randomized, parallel-controlled trial, 102 patients undergoing elective thoracoscopic surgery were randomized 1:1 to thoracic paravertebral block with LB (6.67 mg/mL) or ropivacaine hydrochloride (RH; 0.33%). The primary outcome was opioid consumption within 72 h postoperatively. Secondary outcomes included pain ratings at 6, 12, 24, 48, and 72 h postoperatively; rescue analgesia; time to first ambulation and defecation; post-anesthesia care unit and hospital length of stay; and adverse events. Results: One patient was excluded due to block failure, leaving 101 patients (LB group, n = 51; RH group, n = 50). LB significantly reduced 72-h opioid consumption compared to RH (difference = -181.4 mg; 95% CI: -232.8, -130.0 mg; Conclusion: Ultrasound-guided paravertebral block with LB may reduce postoperative opioid consumption and enhance recovery in patients undergoing thoracic surgery. Trial Registration: Chinese Clinical Trials Registry Platform (chictr.org.cn): ChiCTR2400091217.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.